CVMG 01

Drug Profile

CVMG 01

Alternative Names: CV-MG-01

Latest Information Update: 01 Dec 2015

Price : $50

At a glance

  • Originator CuraVac
  • Class Peptides
  • Mechanism of Action Acetylcholine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Myasthenia gravis

Most Recent Events

  • 01 Nov 2015 Phase-I clinical trials in Myasthenia gravis in Belgium (SC)
  • 01 Jan 2011 CVMG 01 receives Orphan Drug status for Myasthenia gravis in USA
  • 09 Nov 2009 CVMG 01 receives Orphan Drug status for Myasthenia gravis in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top